EUVIMEDEUVIMED entdecken
Multizentrische Studie

Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group

Eirini Katodritou iD, Efstathios Kastritis iD, Dimitra Dalampira iD, Sosana Delimpasi iD, Emmanouil Spanoudakis, Vasiliki Labropoulou, Ioannis Ntanasis-Stathopoulos iD, Annita-Ioanna Gkioka, Nikos Giannakoulas, Nikolaos Kanellias, Theodosia Papadopoulou, Aggeliki Sevastoudi und 13 weitere

American Journal of Hematology · 2023

DOI: 10.1002/ajh.26891 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift American Journal of Hematology, 2023. Verfasst von Eirini Katodritou und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece. Hauptthemen laut MEDLINE: Leukemia, Plasma Cell, Hematopoietic Stem Cell Transplantation, Multiple Myeloma. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated the efficacy and prognostic impact of bortezomib‐lenalidomide triplet (VRd) or daratumumab‐based quadruplets (DBQ) versus previous anti‐myeloma therapies, that is, bortezomib standard combinations (BSC) or conventional chemotherapy (CT), in a large cohort of patients with primary plasma cell leukemia (pPCL), including those fulfilling the revised diagnostic criteria, that is, circulating plasma cells (cPCS): ≥5%; 110 pPCL patients (M/F: 51/59; median age 65 years, range: 44–86) out of 3324 myeloma patients (3%), registered in our database between 2001 and 2021, were studied; 37% had cPCS 5%–19%; 89% received novel combinations including DBQ (21%), VRd (16%) and BSC (52%); 35% underwent autologous stem cell transplantation. 83% achieved objective responses. Treatment with VRd/DBQ strongly correlated with a higher complete response rate (41% vs. 17%; p = .008). After a median follow‐up of 51 months (95% CI: 45–56), 67 patients died. Early mortality was 3.5%. Progression‐free survival was 16 months (95% CI: 12–19.8), significantly longer in patients treated with VRd/DBQ versus BSC/CT (25 months, 95% CI: 13.5–36.5 vs. 13 months 95% CI: 9–16.8; p = .03). Median overall survival (OS) was 29 months (95% CI: 19.6–38.3), significantly longer in patients treated with VRd/DBQ versus BSC/CT (not reached vs. 20 months, 95% CI: 14–26; 3‐year OS: 70% vs. 32%, respectively; p < .001; HzR: 3.88). In the multivariate analysis VRd/DBQ therapy, del17p(+) and PLT

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Plasma CellHematopoietic Stem Cell TransplantationMultiple MyelomaHumansAgedBortezomibGreeceDexamethasoneAntineoplastic Combined Chemotherapy ProtocolsTransplantation, AutologousAntibodies, Monoclonal

Substanzen

BortezomibDexamethasonedaratumumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece.
  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece.
  • Department of Hematology and Bone Marrow Transplantation Unit, Evangelismos Hospital, Athens, Greece.
  • Department of Hematology, University Hospital of Alexandroupolis, Alexandroupoli, Greece.
  • Department of Internal Medicine, Division of Hematology, University of Patras Medical School, Patras, Greece.
  • First Department of Propaedeutic Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.

ORCID-Profile: Eirini Katodritou, Efstathios Kastritis, Dimitra Dalampira, Sosana Delimpasi, Ioannis Ntanasis-Stathopoulos, Ioannis Kostopoulos, Meletios-Athanasios Dimopoulos, Evangelos Terpos

Zitieren

APA

Katodritou, E., Kastritis, E., Dalampira, D., Delimpasi, S., Spanoudakis, E., Labropoulou, V., Ntanasis-Stathopoulos, I., Gkioka, A. I., Giannakoulas, N., Kanellias, N., Papadopoulou, T., Sevastoudi, A., Michalis, E., Papathanasiou, M., Kotsopoulou, M., Sioni, A., Triantafyllou, T., Daiou, A., Papadatou, M., …, & Terpos, E. (2023). Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group. American Journal of Hematology. https://doi.org/10.1002/ajh.26891

Vancouver

Katodritou E, Kastritis E, Dalampira D, Delimpasi S, Spanoudakis E, Labropoulou V, et al. Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group. American Journal of Hematology. 2023. doi:10.1002/ajh.26891

BibTeX
@article{Katodritou2023,
  author = {Katodritou, Eirini and Kastritis, Efstathios and Dalampira, Dimitra and Delimpasi, Sosana and Spanoudakis, Emmanouil and Labropoulou, Vasiliki and Ntanasis-Stathopoulos, Ioannis and Gkioka, Annita-Ioanna and Giannakoulas, Nikos and Kanellias, Nikolaos and Papadopoulou, Theodosia and Sevastoudi, Aggeliki and Michalis, Eyrydiki and Papathanasiou, Maria and Kotsopoulou, Maria and Sioni, Anastasia and Triantafyllou, Theodora and Daiou, Aikaterini and Papadatou, Mavra and Kyrtsonis, Marie-Christine and Pouli, Anastasia and Kostopoulos, Ioannis and Verrou, Evgenia and Dimopoulos, Meletios-Athanasios and Terpos, Evangelos},
  title = {Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study group},
  journal = {American Journal of Hematology},
  year = {2023},
  doi = {10.1002/ajh.26891}
}
Kostenlos starten →